# US 2022/0031670 A1 · Pharmaceutical combinations for use in the treatment of neoplastic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031670 A1
- Document ID: US20220031670A1
- Status: Published application
- Kind: A1
- Application number: 17/275,727
- Filed: 2019-09-19
- Published: 2022-02-03
- Earliest claimed: 2018-09-20
- Assignees: Basilea Pharmaceutica International AG
- Applicants: Basilea Pharmaceutica International AG
- Inventors: Felix BACHMANN; Heidi LANE; Paul MCSHEEHY
- Web page: https://patentgrep.com/patent/US20220031670A1

## CPC

- A61K 31/4245: Oxadiazoles
- C07D 413/02: containing two hetero rings
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61P 35/00: Antineoplastic agents
- C07D 413/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides pharmaceutical combinations comprising (a) a compound of formula (I) wherein R represents phenyl or pyridinyl; wherein phenyl is optionally substituted by one or two substituents independently selected from lower alkyl, lower alkoxy, hydroxyl, amino, lower alkylamino, lower dialkylamino, acetylamino, halogen and nitro; and wherein pyridinyl is optionally substituted by amino or halogen; R1 represents hydrogen or cyano-lower alkyl; and wherein the prefix lower denotes a radical having up to and including a maximum of 4 carbon atoms; or a pharmaceutically acceptable derivative thereof; and (b) a compound of Formula (II) (gemcitabine) or a pharmaceutically acceptable salt thereof and the use of the pharmaceutical combinations in the treatment of neoplastic diseases.

## Claims

### Claim 1

A pharmaceutical combination, comprising (a) a compound of formula I:
wherein:
R represents phenyl or pyridinyl;
wherein phenyl is optionally substituted by one or two substituents independently selected from lower alkyl, lower alkoxy, hydroxyl, amino, lower alkylamino, lower dialkylamino, acetylamino, halogen and nitro;
and wherein pyridinyl is optionally substituted by amino or halogen;
R1 represents hydrogen or cyano-lower alkyl;
and wherein the prefix lower denotes a radical having up to and including a maximum of 4 carbon atoms; or a pharmaceutically acceptable derivative thereof,
and (b) a compound of formula II (gemcitabine)
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The pharmaceutical combination according to claim 1, wherein the compound of formula I, or pharmaceutically acceptable derivative thereof, is a compound of formula I-A:
or a pharmaceutically acceptable salt thereof, or a compound of formula I-B:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The pharmaceutical combination according to claim 2, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is the dihydrochloride salt of the compound of formula I-B and wherein the compound of formula II or a pharmaceutically acceptable salt thereof is gemcitabine hydrochloride.

### Claim 4 (depends on 1)

The pharmaceutical combination according to claim 1, wherein the mole ratio of the mole amount of the compound of formula II or pharmaceutically acceptable salt thereof to the mole amount of the compound of formula II or pharmaceutically acceptable derivative thereof is 2:1 to 340:1.

### Claim 5 (depends on 1)

A method for the treatment of a neoplastic disease in a subject in need thereof, comprising the step of administering the pharmaceutical combination according to claim 1 to said subject.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the compound of formula I or pharmaceutically acceptable derivative thereof and of the compound of formula II or pharmaceutically acceptable salt thereof are administered to the subject according to cyclic treatment schedules;
wherein when the treatment cycles are of the same duration the mole ratio of the total mole amount of the doses of the compound of formula II or pharmaceutically acceptable salt thereof to the total mole amount of the doses of the compound of formula I or pharmaceutically acceptable derivative thereof administered to the subject over the respective treatment cycles is 2:1 to 340:1;
and wherein when the treatment cycles are of different duration the ratio of the total mole amount of the doses of the compound of formula II or pharmaceutically acceptable salt thereof to the total mole amount of the doses of the compound of formula II or pharmaceutically acceptable derivative thereof administered to the subject over a theoretical period of time corresponding to a common multiple of the duration of the respective treatment cycles is 2:1 to 340:1.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is administered to the subject according to a continuous treatment schedule and the compound of formula II or pharmaceutically acceptable salt thereof is administered to the subject according to a cyclic treatment schedule and wherein the mole ratio of the total mole amount of the doses of the compound of formula II or pharmaceutically acceptable salt thereof administered to the subject over a treatment cycle to the mole amount of the doses of the compound of formula I or derivative thereof over a period of the same duration of the treatment cycle of the compound of formula II or pharmaceutically acceptable salt thereof is 2:1 to 340:1.

### Claim 8 (depends on 5)

The method according to claim 5, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is administered orally at dose corresponding to the mole equivalent of about 2 mg to about 30 mg of the dihydrochloride salt of the compound of formula I-B per day on days when administered, and wherein the compound of formula II or pharmaceutically acceptable salt thereof is administered intravenously at a dose corresponding to the mole equivalent of Gemcitabine hydrochloride of 100 mg/m2 to 1400 mg/m2 per week during weeks when administered.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is administered to the subject at least once per day, and wherein the compound of formula II or pharmaceutically acceptable salt thereof is administered to the subject according to a 21-day treatment cycle with administration initiated on days 1 and 8, or according to a 28-day treatment cycle with administration initiated on days 1, 8 and 15.

### Claim 10 (depends on 5)

The method according to claim 5, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is administered intravenously at a dose corresponding to the mole equivalent of about 15 mg/m2 to about 160 mg/m2 of the dihydrochloride salt of the compound of formula I-B per week during weeks when administered, and wherein the compound of formula II or pharmaceutically acceptable salt thereof is administered intravenously at a dose corresponding to the mole equivalent of gemcitabine hydrochloride of about 100 mg/m2 to 1400 mg/m2 per week during weeks when administered.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the compound of formula I or pharmaceutically acceptable derivative thereof is administered according to a 21-day treatment cycle with administration initiated on days 1 and 8, or a 28-day treatment cycle with administration initiated on days 1, 8 and 15, and wherein the compound of formula II or pharmaceutically acceptable salt thereof is administered according to a 21-day treatment cycle with administration initiated on days 1 and 8, or according to a 28-day treatment cycle with administration initiated on days 1, 8 and 15.

### Claim 12 (depends on 5)

The method according to claim 5, wherein the neoplastic disease is selected from the group consisting of epithelial neoplasms, squamous cell neoplasms, basal cell neoplasms, transitional cell papillomas and carcinomas, adenomas and adenocarcinomas, adnexal and skin appendage neoplasms, mucoepidermoid neoplasms, cystic neoplasms, mucinous and serous neoplasms, ducal-, lobular and medullary neoplasms, acinar cell neoplasms, complex epithelial neoplasms, specialized gonadal neoplasms, paragangliomas and glomus tumours, naevi and melanomas, soft tissue tumours and sarcomas, fibromatous neoplasms, myxomatous neoplasms, lipomatous neoplasms, myomatous neoplasms, complex mixed and stromal neoplasms, fibroepithelial neoplasms, synovial like neoplasms, mesothelial neoplasms, germ cell neoplasms, trophoblastic neoplasms, mesonephromas, blood vessel tumours, lymphatic vessel tumours, osseous and chondromatous neoplasms, giant cell tumours, miscellaneous bone tumours, odontogenic tumours, gliomas, neuroepitheliomatous neoplasms, meningiomas, nerve sheath tumours, granular cell tumours and alveolar soft part sarcomas, Hodgkin's and non-Hodgkin's lymphomas, other lymphoreticular neoplasms, plasma cell tumours, mast cell tumours, immunoproliferative diseases, leukemias, myeloproliferative disorders, lymphoproliferative disorders and myelodysplastic syndromes.

### Claim 13 (depends on 5)

The method according to claim 5, wherein the disease is a cancer.

### Claim 14 (depends on 1)

A method for the treatment of a neoplastic disease in a subject in need thereof, comprising the step of administering a compound of formula I, or a pharmaceutically acceptable derivative thereof, as defined in claim 1 in combination with a compound of formula II, or pharmaceutically acceptable salt thereof, as defined in claim 1.

### Claim 15 (depends on 1)

A method for the treatment of a neoplastic disease in a subject in need thereof, comprising the step of administering to said subject a compound of formula II, or pharmaceutically acceptable salt thereof, as defined in claim 1 in combination with a compound of formula I, or pharmaceutically acceptable derivative thereof, as defined in claim 1.

### Claim 16 (depends on 5)

The method according to claim 5, wherein said subject is a human.

### Claim 17 (depends on 13)

The method according to claim 13, wherein said cancer is selected from lung cancer (including non-small cell lung cancer and mesothelioma), pancreatic cancer (including ductal adenocarcinoma and metastatic pancreatic cancer), bladder cancer, ovarian cancer (including ovarian carcinoma), biliary tract cancer, peripheral or cutaneous T-cell lymphoma, non-Hodgkins lymphoma and breast cancer.

### Claim 18 (depends on 13)

The method according to claim 13, wherein said cancer is pancreatic cancer.

### Claim 19 (depends on 14)

The method according to claim 14, wherein said subject is a human.

### Claim 20 (depends on 15)

The method according to claim 15, wherein said subject is a human.

### Claim 21 (depends on 15)

The method according to claim 15, wherein the neoplastic disease is a cancer selected from lung cancer (including non-small cell lung cancer and mesothelioma), pancreatic cancer (including ductal adenocarcinoma and metastatic pancreatic cancer), bladder cancer, ovarian cancer (including ovarian carcinoma), biliary tract cancer, peripheral or cutaneous T-cell lymphoma, non-Hodgkins lymphoma and breast cancer.

### Claim 22 (depends on 15)

The method according to claim 15, wherein the neoplastic disease is pancreatic cancer.
